Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

s, cancer and potentially other therapeutic areas of interest to AstraZeneca."

"Regulus is pleased to form another significant strategic alliance on microRNA therapeutics," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics Inc. "AstraZeneca is a global, innovation-driven company that we believe can greatly aid our efforts to advance microRNA therapeutics to the clinic and the market. The entire field of RNA therapeutics has been rapidly advancing, reaching significant milestones recently. We are committed to realize the broad utility of these new RNA-based medicines to treat human disease in the future. "

Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics Inc., added, "We wanted to partner our microRNA-33 program with AstraZeneca due to their excellent track record on developing and commercializing drugs in cardiovascular and metabolic diseases and their commitment to the RNA therapeutic field.  We look forward to growing our strategic relationship with AstraZeneca with additional targets to develop important first-in-class medicines."

About microRNA-33 for Atherosclerosis

Atherosclerosis is the build-up of plaque that occurs when cholesterol and inflammatory cells accumulate in blood vessels. These plaques can rupture, leading to slowing or blockage of blood flow and ultimately resulting in a heart attack or stroke. Scientific research has shown a strong correlation between high cholesterol levels and cardiovascular disease which, according to the Centers for Disease Control, is the leading cause of death in the United States.

Regulus' lead program for atherosclerosis targets microRNA-33, which has a unique mechanism of action for the management of cholesterol levels. The inhibition of microRNA-33 with our anti-miRs promotes reverse cholesterol transport, or RCT, which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells calle
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company,s ... the position of President and Chief Executive Officer, effective ... Chief Executive Officer in May 2010, and prior thereto ...
... Inc., today reported positive clinical trial results on ... inhalation), an antibiotic that is entering Phase III ...  The results demonstrate significant clinical benefit and complete ... of lung infections due to the bacterium, ...
Cached Medicine Technology:PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 2PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 2ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 4ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 5
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, defines ... with an in-depth analysis and forecasting of revenues. ... this market with insights on trends, opportunities, and ... 36 figures spread through 157 pages and in-depth ... http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers will ...
(Date:7/24/2014)... Four Seasons Resort Maui at Wailea ... million renovation of the famed Maile suite and the ... in time to welcome summer guests vacationing to this ... the internationally-acclaimed BraytonHughes Design Studios, San Francisco and London, ... the largest in Hawaii—received a complete re-envisioning. No stranger ...
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Just as ... they must consider their own financial and marketing strength ... weak marketing campaigns to the next level by using ... Call Center, IVR, Voice Broadcast, Call Tracking and ... 98% open rate, text messages are quickly become integral ...
(Date:7/24/2014)... 24, 2014 In a July 9th article ... founder of Lotus Blossom Consulting LLC , was quoted ... Three Ways to Cut the High Cost of Infertility . ... costs is to maximize your chance of success from the ... a clinic. , “I am always happy to talk ...
Breaking Medicine News(10 mins):Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
... 3 The National,Fibromyalgia Association today announced that ... III, will be its designated spokeswoman to,help raise ... illness that experts believe affects up to 10 ... Mrs. Bremer was diagnosed with fibromyalgia 25 ...
... join Terrence Howard, Natalie, Maines and Abigail Breslin to ... ... SAN FRANCISCO, Oct. 3 Gap is proud to,introduce ... to help eliminate AIDS in Africa. Captured by acclaimed,photographer Annie ...
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... on the,company,s 510(k) application to the US Food ... On Wednesday, October 3, 2007, Dr. Brent ... present at BioContact Quebec, a leading,annual biopharmaceutical conference. ...
... New research from the Howard Florey Institute in Melbourne ... cause epilepsy in infants. , Infants are more susceptible ... rapid rate, making their brain cells excitable. Their neurons ... cells, which can disrupt normal brain activity and results ...
... Laboratory (EMBL), the University of Helsinki, Finland, the ... officially launch their new Nordic EMBL Partnership for ... and collaborations between the partners and will facilitate ... for an initial period of five years. ...
... spur these outbursts , WEDNESDAY, Oct. 3 (HealthDay News) ... problems can help prompt dogs to bite children, a ... Pennsylvania looked at 111 cases involving 103 dogs that ... clinic over four years. , "Guarding of resources and ...
Cached Medicine News:Health News:Frances Winfield Bremer, Wife of Ambassador L. Paul Bremer, III, to Become Spokeswoman for the National Fibromyalgia Association 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 3Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 4Health News:PreMD Inc. Provides Corporate Update 2Health News:PreMD Inc. Provides Corporate Update 3Health News:Research shows how genetic mutation causes epilepsy in infants 2Health News:EMBL reaches north 2Health News:Medical, Behavioral Woes Can Drive Dogs to Bite 2
... for strength and durability. Four 64 mirrors ... minimal lens rotation. Choice of three handles ... Small diameter contact surface allows static or ... polymer coating protects mirrors and is compatible ...
... Three mirrors of 64, 67 ... diameter contact surface for use ... be viewed through the central ... polymer coating protects mirrors and ...
Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
Medicine Products: